Provided by Tiger Fintech (Singapore) Pte. Ltd.

Astria Therapeutics Inc

5.08
+0.12002.42%
Volume:51.77K
Turnover:263.26K
Market Cap:286.69M
PE:-3.03
High:5.16
Open:5.06
Low:5.06
Close:4.96
Loading ...

Company Profile

Company Name:
Astria Therapeutics Inc
Exchange:
NASDAQ
Establishment Date:
2008
Employees:
78
Office Location:
22 Boston Wharf Road,10th floor,Boston,Massachusetts,United States
Zip Code:
02210
Fax:
617 273 2637
Introduction:
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Directors

Name
Position
Jill C. Milne
President, Chief Executive Officer and Director
Kenneth Bate
Director and Co-Chairman
Michael Ross
Director and Co-Chairman
Burt Adelman
Director
Jean George
Director
Michael D. Kishbauch
Director

Shareholders

Name
Position
Jill C. Milne
President, Chief Executive Officer and Director
Andrew Nichols
Chief Scientific Officer
Deirdre A. Cunnane
Chief Legal Officer and Treasurer
Joanne M. Donovan
Chief Medical Officer